Income Statement (TTM)
Cyclacel Pharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 4.29 | 7.97 | 6.90 | -82.18 | -7.50 | -41.89 | -67.44 | -28.57 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | |||||||||
| Change (%) | |||||||||
| % of Revenue | |||||||||
| Gross Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 4.29 | 7.97 | 6.90 | -82.18 | -7.50 | -41.89 | -67.44 | -28.57 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| SG&A | 7 | 7 | 7 | 7 | 7 | 6 | 5 | 8 | 8 |
| Change (%) | -6.25 | -3.86 | -0.92 | 0.18 | -5.26 | -14.64 | 48.48 | -4.47 | |
| % of Revenue | 1,998.38 | 1,796.40 | 1,599.52 | 1,482.43 | 8,335.06 | 8,536.49 | 12,539.53 | 57,186.69 | 76,480.00 |
| R&D | 21 | 22 | 19 | 16 | 14 | 9 | 7 | 5 | 3 |
| Change (%) | 4.00 | -14.25 | -15.00 | -16.37 | -31.75 | -28.39 | -29.48 | -42.04 | |
| % of Revenue | 5,758.46 | 5,742.67 | 4,560.71 | 3,626.26 | 17,019.94 | 12,558.11 | 15,476.74 | 33,520.45 | 27,200.00 |
| OpEx | 29 | 29 | 26 | 23 | 20 | 16 | 12 | 13 | 10 |
| Change (%) | 1.36 | -11.78 | -11.34 | -11.57 | -23.04 | -22.83 | 5.41 | -18.36 | |
| % of Revenue | 7,756.84 | 7,539.07 | 6,160.24 | 5,108.69 | 25,355.00 | 21,094.59 | 28,016.28 | 90,707.14 | 103,680.00 |
| Operating Income | -29 | -29 | -25 | -22 | -20 | -16 | -12 | -13 | -10 |
| Change (%) | 1.32 | -12.04 | -11.64 | -10.16 | -23.10 | -22.73 | 5.67 | -18.34 | |
| % of Revenue | -7,656.84 | -7,439.07 | -6,060.24 | -5,008.69 | -25,255.00 | -20,994.59 | -27,916.28 | -90,607.14 | -103,580.00 |
| Interest Expense | -0 | -0 | |||||||
| Change (%) | -30.77 | ||||||||
| % of Revenue | -32.50 | -24.32 | |||||||
| Net Income | -24 | -25 | -23 | -20 | -18 | -13 | -11 | -8 | -6 |
| Change (%) | 3.94 | -8.70 | -12.67 | -11.12 | -23.28 | -16.52 | -25.55 | -23.23 | |
| % of Revenue | -6,371.85 | -6,350.39 | -5,370.24 | -4,386.86 | -21,882.50 | -18,150.00 | -26,074.42 | -59,621.43 | -64,080.00 |
Source: Capital IQ
